Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

Saved in:
Bibliographic Details
Main Authors: Conchon,Monika, Freitas,Carla Maria Boquimpani de Moura, Rego,Maria Aparecida do Carmo, Braga Junior,José Wilson Ramos
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items